BERG Health is a Boston-local biotech that leverages AI and patient biology to accelerate drug discovery and development for oncology, neurology, and rare diseases. They partner with the likes of Boehringer Ingelheim, Sanofi, AstraZeneca, among others, to drive key drug development. BERG is also working with the US Department of Energy's Oak Ridge National Lab to blend BERG's AI platform with the Summit supercomputer to map out and repurpose drugs. They intend to help stop the progression of COVID-19 in patients. The company also recently announced a new study published in the Journal of Racial and Ethnic Health Disparities, which they conducted in collaboration with the University of Oxford and Virginia Commonwealth. The study identifies why COVID-19 is more prevalent in African American populations and how to treat it using existing ACE inhibitors and ARBs. Dr. Niven R. Narain is Co-Founder, President & CEO of Berg, discusses what they are working on across all working drug pipelines and biotech's future amid and beyond COVID. Today's guest is a pioneer in technology development at the intersection of Biology and AI and is the inventor of the Interrogative Biology® platform. It has unraveled actionable disease insight leading to de novo and repurposed development of a deep pipeline of oncology products, metabolic, rare, and CNS diseases. Namely, BPM 31510 currently in Phase 2 trials for cancer covered by over 650 issued and pending US and international patents.